Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX0G4F)

Drug Name
PHENETHYLAMINE Drug Info
Synonyms
Phenethylamine; 2-phenylethylamine; 2-Phenylethanamine; 64-04-0; Benzeneethanamine; phenylethylamine; 2-Phenethylamine; beta-phenylethylamine; beta-Phenethylamine; 1-Amino-2-phenylethane; beta-Aminoethylbenzene; (2-Aminoethyl)benzene; 2-Amino-1-phenylethane; 1-Phenyl-2-aminoethane; Ethylamine, 2-phenyl-; Ethanamine, 2-phenyl-; 2-Phenylethan-1-Amine; 1-Phenyl-2-amino-athan; 2-Fenylethylamin; 2-Amino-fenylethan; 2-Fenylethylamin [Czech]; PHENETHYLAMINE, BETA; 2-Amino-fenylethan [Czech]; beta-Phenylaethylamin [German]
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1001
ChEBI ID
CHEBI:18397
CAS Number
CAS 64-04-0
TTD Drug ID
DMX0G4F
INTEDE Drug ID
DR1960

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [9]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [10]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [11]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [12]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [13]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [14]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [15]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [16]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [17]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Monoamine oxidase type A (MAO-A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epinephrine DM3KJBC Acute asthma CA23 Approved [19]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [20]
Naratriptan DMO50U2 Headache 8A80-8A84 Approved [21]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [22]
Almotriptan malate DMFG5ST N. A. N. A. Approved [23]
SEROTONIN DMOFCRY Discovery agent N.A. Investigative [3]
Benzylamine DMRM6ES N. A. N. A. Investigative [3]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Metabolized By Copper amine oxidase (AOC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tresperimus DMOVBSF Autoimmune diabetes 5A10 Discontinued in Phase 3 [24]
tyramine DM4UXT1 Discovery agent N.A. Investigative [4]
Benzylamine DMRM6ES N. A. N. A. Investigative [4]
Methylamine DMTPL4W N. A. N. A. Investigative [4]
Drug(s) Metabolized By Semicarbazide-sensitive amine oxidase (AOC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
tyramine DM4UXT1 Discovery agent N.A. Investigative [4]
Benzylamine DMRM6ES N. A. N. A. Investigative [4]
Methylamine DMTPL4W N. A. N. A. Investigative [4]
Drug(s) Affected By Alpha-2A adrenergic receptor (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [25]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [26]
Rilmenidine DM13PQW Hypertension BA00-BA04 Approved [27]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [28]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [29]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [30]
Oxymetazoline DM8ZXT6 Arrhythmia BC9Z Approved [31]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [32]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [33]
Indapamide DMGN1PW Edema MG29 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-2C adrenergic receptor (ADRA2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [35]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [36]
Oxymetazoline DM8ZXT6 Arrhythmia BC9Z Approved [31]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [33]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [37]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [38]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [39]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [40]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [41]
Xylometazoline DMKV32D Allergic rhinitis CA08.0 Phase 4 [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Trace amine-associated receptor 1 (TAAR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [8]
Octopamine DMLQVTJ Thrombosis DB61-GB90 Discontinued in Phase 2a [8]
Drug(s) Affected By Sodium-dependent dopamine transporter (SLC6A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [42]
Amphetamine DMSZQAK Attention deficit hyperactivity disorder 6A05.Z Approved [43]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [44]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [45]
Testosterone DM7HUNW Hot flushes GA30 Approved [46]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [33]
Dextroamphetamine DMMIHVP Attention deficit hyperactivity disorder 6A05.Z Approved [47]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [41]
Permethrin DMZ0Q1G Pediculus capitis infestation 1G00.0 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Arylamine N-acetyltransferase 2 (NAT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [49]
Hydralazine DMU8JGH Chronic heart failure BD1Z Approved [50]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [51]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [52]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [53]
Quercetin DM3NC4M Obesity 5B81 Approved [54]
Testosterone DM7HUNW Hot flushes GA30 Approved [46]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [55]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Monoamine oxidase type A (MAO-A) DERE4TU AOFA_HUMAN Substrate [3]
Copper amine oxidase (AOC3) DE6SOC5 AOC3_HUMAN Substrate [4]
Semicarbazide-sensitive amine oxidase (AOC2) DE8DP90 AOC2_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-2A adrenergic receptor (ADRA2A) OTZFGOTP ADA2A_HUMAN Protein Interaction/Cellular Processes [5]
Alpha-2C adrenergic receptor (ADRA2C) OT5B9RKP ADA2C_HUMAN Protein Interaction/Cellular Processes [5]
Arylamine N-acetyltransferase 2 (NAT2) OTBPDQOY ARY2_HUMAN Biotransformations [6]
Sodium-dependent dopamine transporter (SLC6A3) OT39XG28 SC6A3_HUMAN Regulation of Drug Effects [7]
Trace amine-associated receptor 1 (TAAR1) OTUY8CGM TAAR1_HUMAN Gene/Protein Processing [8]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2144).
2 Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.
3 Do monomeric vs dimeric forms of MAO-A make a difference? A direct comparison of the catalytic properties of rat and human MAO-A's. J Neural Transm (Vienna). 2007;114(6):721-4.
4 The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase. Cell Mol Life Sci. 2009 Aug;66(16):2743-57.
5 Effects of synephrine and beta-phenethylamine on human alpha-adrenoceptor subtypes. Planta Med. 2010 Jul;76(10):981-6. doi: 10.1055/s-0029-1240884. Epub 2010 Mar 9.
6 N-acetyltransferase 2 genetic polymorphism modifies genotoxic and oxidative damage from new psychoactive substances. Arch Toxicol. 2023 Jan;97(1):189-199. doi: 10.1007/s00204-022-03383-2. Epub 2022 Sep 23.
7 Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther. 2005 Jun;313(3):983-94. doi: 10.1124/jpet.105.084459. Epub 2005 Mar 11.
8 Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. Biochem J. 2009 Oct 23;424(1):39-45. doi: 10.1042/BJ20090998.
9 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
10 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
11 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
12 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
13 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
14 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
16 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
17 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
18 Clinical pipeline report, company report or official report of Lundbeck.
19 Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294.
20 Med-psych drug-drug interactions update. Psychosomatics. 2002 May;43(3):245-7.
21 Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.
22 Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.
23 Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
24 Metabolism of tresperimus by rat aorta semicarbazide-sensitive amine oxidase (SSAO). Fundam Clin Pharmacol. 2002 Dec;16(6):461-70.
25 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
26 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
27 Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. doi: 10.1038/sj.bjp.0702429.
28 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
29 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
30 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
31 Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
32 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
33 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
34 Platelet alpha 2-adrenoceptor modifications induced by long-term treatment with indapamide in essential hypertension. Am J Med. 1988 Jan 29;84(1B):31-5.
35 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
36 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
37 Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
38 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
39 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
40 Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
41 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
42 Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca(2+) channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513. doi: 10.1016/j.taap.2021.115513. Epub 2021 Mar 27.
43 Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9. doi: 10.1038/sj.npp.1300637.
44 Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem. 2016 Oct 14;291(42):22053-22062. doi: 10.1074/jbc.M116.749119. Epub 2016 Aug 23.
45 Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in?vivo assays in mice. Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.
46 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
47 Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100. doi: 10.1016/j.neuro.2019.02.011. Epub 2019 Feb 15.
48 Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicol Appl Pharmacol. 2006 Mar 15;211(3):188-97. doi: 10.1016/j.taap.2005.06.003. Epub 2005 Jul 11.
49 Interindividual variability in 5-Fluorouracil metabolism and procainamide N-acetylation in human liver cytosol. Biol Pharm Bull. 2005 Jun;28(6):1071-4. doi: 10.1248/bpb.28.1071.
50 Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 2005 Jan 15;69(2):347-59. doi: 10.1016/j.bcp.2004.09.014. Epub 2004 Nov 24.
51 Association analysis of N-acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics. Pharmacogenomics. 2010 Jul;11(7):951-8. doi: 10.2217/pgs.10.65.
52 Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J. 2007 Apr;7(2):144-52. doi: 10.1038/sj.tpj.6500407. Epub 2006 Jul 18.
53 The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol Pharmacol. 2005 Apr;67(4):1299-306.
54 Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin Exp Pharmacol Physiol. 2009 Aug;36(8):828-33.
55 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
56 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
57 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.